



alzchem
group

AGILE SCIENCE PURE RESULTS

alzchem
group



Q2

2024

ANDREAS NIEDERMAIER, CEO
DR. GEORG WEICHSELBAUMER, CSO
ANDREAS LÖSLER, CFO

August 1, 2024

DISCLAIMER

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements about the business, financial condition and earnings performance of the Alzchem Group. These statements are based on assumptions and projections resting upon currently available information and present estimates. They are subject to a multitude of uncertainties and risks. Actual business development may therefore differ materially from what has been expected. Beyond disclosure requirements stipulated by law, Alzchem does not undertake any obligation to update forward-looking statements.

Unless stipulated otherwise, all values are rounded up or down in accordance with the commercial rounding practices. Please note that differences can result from the use of rounded amounts and percentages.

AGENDA – ANALYST PRESENTATION Q2 2024

- I. **Executive Summary**
- II. Business and financial details
- III. Back-Up

HIGHLIGHTS

Strong half year performance leads to an increase in EBITDA outlook



Group sales above previous year with strong shifts between segments

Strong increase in EBITDA as a result from sales shifts to Specialty Chemicals



Net result with 78 % increase compared to previous year followed by 65 % increase in free cashflow



EBITDA outlook 2024 adjusted:
Further growth to over 100 M€ expected


Sales outlook 2024 confirmed with more shift to Specialty Chemicals



Implementation of climate roadmap is progressing as planned – also thanks to government funding



Share price increase of more than 40 % within first six months of 2024




Ongoing strong market situation in niche markets

OUTLOOK 2024 (in M€)




Outlook adjusted; strong growth in EBITDA; sales confirmed

SALES



EBITDA



COMMENTS

- Based on strong half year figures EBITDA outlook was raised
 - EBITDA expected to increase to over 100 M€
 - Most probable expectation is a linear development from half year figures
- Sales outlook for 2024 confirmed
 - Expected increase to approx. 570 M€
 - Revenue mix is expected to shift more to Specialty Chemicals
- Main driver of EBITDA development is the continued revenue shift to higher margin specialty products with growth in
 - Dietary supplements
 - Animal nutrition
 - Defense
- EBITDA margin expected to raise to over 17.5 %
- All other performance measures are confirmed; statements from year end report are still valid

AGENDA – ANALYST PRESENTATION Q2 2024

- I. Executive Summary
- II. Business and financial details**
- III. Back-Up



NITRALZ®

Perlka®
CALCIUM CYANAMIDE

CaD

BASICS & INTERMEDIATES


The "Basics & Intermediates" segment comprises the production of basic and intermediate products that are marketed as independent products for example in agriculture, steel production and the automotive sector and as raw materials for the manufacture of specialty chemicals.

BASICS & INTERMEDIATES SEGMENT (in M€)


Challenging market environment with stable EBITDA



SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q2 | DELTA 01 - 06 |
|----------|----------|---------------|
| Volume | - 3.2% | - 5.1% |
| Price | - 5.8% | - 6.5% |
| Currency | - 0.1% | - 0.2% |

COMMENTS

- Sales decrease of 12 % in first half year 2024
 - Combination of price and volume impacts
 - Volume decline is still required and accepted if prices are not healthy
 - Price reductions follow price escalation clauses on energy and raw materials
- Nitralz® business continues to face strong price competition from Asian competitors
- Perlka® business with increasing demand
- Pricing strategy leads to stable EBITDA development while margins could be improved
 - 5.3 % EBITDA margin vs. 5.0 % in H1 comparison



CREAMINO Dormex® Bioselect® **DYHARD®**  **Creasure®**

SPECIALTY CHEMICALS


The "Specialty Chemicals" segment produces and sells high-quality growth products in the area of specialty chemicals.

SPECIALTY CHEMICALS SEGMENT (in M€)




Ongoing growth trend accompanied by profitability increase


SALES




EBITDA



SALES



EBITDA



SALES ANALYSIS

| | DELTA Q2 | DELTA 01 - 06 |
|----------|----------|---------------|
| Volume | + 16.2% | + 11.4% |
| Price | + 0.7% | + 1.1% |
| Currency | + 0.3% | - 0.1% |

COMMENTS

- 12 % sales increase within first six months mainly caused by volume effects
- Dietary supplements, animal nutrition and defense business with ongoing increased demand
- Automotive und pharma markets with positive developments while custom synthesis is still linked to the overall economics within chemical industry
- EBITDA development supported by
 - Stable pricing strategy
 - High and constant utilization of plants with more efficient production
- Positive development of EBITDA margin:
 - 25.5 % EBITDA margin vs. 19.0 % in H1 comparison



OTHER & HOLDING


The "Other & Holding" segment offers infrastructure and energy supply services at our locations for the chemicals segments and for external customers.

OTHER & HOLDING SEGMENT (in M€)


Segment in line with Outlook




SALES




EBITDA



SALES



EBITDA



COMMENTS

- Sales increases from the passing on of cost increases to the chemical park customers.
- The services used by Alzchem's chemical park customers were primarily of a variable nature (energy supply, technical services and network operation).
- 8.5 % EBITDA-margin in first six months compared to 6.2 % in 2023
- Overall stable development

FINANCIAL OVERVIEW

Continued growth in all major performance figures



| Alzchem Group | Q2 2023 | Q2 2024 | qoq % | 2023 1 - 6 | 2024 1 - 6 | yoy % |
|---------------------------|------------|------------|---------|---------------|---------------|---------|
| SALES (in M€) | 126,6 | 136,2 | +7,6% | 277,0 | 286,3 | +3,3% |
| EBITDA (in M€) | 17,9 | 27,0 | +51,2% | 36,8 | 51,9 | +41,2% |
| EBITDA margin (in %) | 14,1% | 19,8% | +5,7 pp | 13,3% | 18,1% | +4,9 pp |
| Earnings per Share (in €) | 0,71 | 1,41 | +99,9% | 1,46 | 2,61 | +78,8% |

- Group Sales within six months period increased by 3.3% to 286.3 M€
- Different developments in our operating segments; volume growth in Specialty Chemicals overcompensating price and volume declines in basic & intermediates
- EBITDA strongly impacted by continuous revenue shift to Specialty Chemicals segment, increase by 41 % to EUR 52 million
- Improved EBITDA-margin of 18.1% (previous year: 13.3%) supported by both operating segments
- Strong increase in net result and earnings per share as EBITDA increase was supported by better financial result


| SALES ANALYSIS | DELTA Q2 | DELTA 01 - 06 |
|-------------------|-------------|------------------|
| Volume | +9.0% | +5.1% |
| Price | -1.5% | -1.7% |
| Currency | +0.2% | -0.1% |

BALANCE SHEET (in M€)


Increase in equity and cash dominates balance sheet development



ASSETS



LIABILITIES




- Strong cashflow results in an increase of 34 M€ in cash since December 31, 2023, and is the main driver for increased total assets (+39 M€)
- Deferred tax assets lower due to interest-related decline in pension provisions; other non-current assets slightly increased
- Inventories stable on same level as per 31/12/2023
- Trade receivables stable with less impact from factoring; no changes in customers payment behavior

- Equity increase (19 M€) supports development of equity ratio to 39.4%
- High net income from first half year 2024 (+26.7 M€) as well as increased interest for pension provision (+4.5 M€) positively influenced equity; dividend payment reduced equity (-12.2 M€)
- Pension obligation decreased by 5.6 M€ following development of interest rate for pension provision from 3.2% to 3.6%
- Increase in current liabilities due to higher sales volumes
- Repayment of bank liabilities on schedule

CASHFLOW (in M€)

Strong increase in operating cashflow leads to stable financial position



- Strong operating cashflow at 64 M€ reflects stable finance position of Alzchem (+24 M€ compared to last year); main driver is the positive operating result and very strict working capital management
- Investment activities on higher level compared to last year's cautious investment policy; focus on completion of the photovoltaic park, expansion of creatine capacities and infrastructure measures
- Free cashflow increased to 51.4 M€ compared to 31.2 M€ from previous year

- Cashflow from financing activities impacted by dividend payments of 12.2 M€ and scheduled loan repayments
- Based on the good cashflow situation the usage of working capital lines and factoring was not required
- Overall cash and cash equivalents increased by 34 M€ to 46 M€ since December 31, 2023
- Alzchem is well positioned for further growth investments

FINANCIAL CALENDAR

Upcoming dates*



- | | | |
|-----------|------|---|
| SEP 23 | 2024 | Baader Investment Conference |
| SEP 25 | 2024 | Berenberg and Goldman Sachs German Corporate Conference |
| NOV 7 | 2024 | Quarterly Statement 3 rd Quarter 2024 |
| NOV 13 | 2024 | Münchener Kapitalmarkt Konferenz |
| NOV 25-26 | 2024 | Deutsches Eigenkapitalforum |

*subject to change

FEEDBACK

We appreciate your feedback



Were your expectations met?
Are you missing any content?

WE APPRECIATE YOUR FEEDBACK!

[Link](#)

QR-Code



**AGILE SCIENCE
PURE RESULTS**

**alzchem
group**



Investor Relations

T +49 8621 86-2888

F +49 8621 86-502888

ir@alzchem.com

AGENDA – ANALYST PRESENTATION Q2 2024

- I. Executive Summary
- II. Business and financial details
- III. Back-Up**

BALANCE SHEET

Alzchem Group




| ALZCHEM GROUP (IN T€) | 31.12.2023 | 30.06.2024 | Deviation | |
|---|----------------|----------------|---------------|--------------|
| Intangible assets | 3,664 | 3,702 | 38 | 1.0% |
| Tangible assets | 177,281 | 179,138 | 1,857 | 1.0% |
| Investment properties | | | | |
| Right of use (assets) | 4,855 | 4,383 | -472 | -9.7% |
| Investments accounted for using the equity method | | | | |
| Financials assets | 5 | 5 | | |
| Trade receivables | | | | |
| Other receivables | 1,371 | 1,349 | -22 | -1.6% |
| <i>there of Deferred tax assets for pensions provisions</i> | | | | |
| Deferred tax assets | 20,921 | 18,923 | -1,997 | -9.5% |
| SUM NON-CURRENT ASSETS | 208,096 | 207,500 | -596 | -0.3% |
| Inventories | 107,479 | 107,918 | 439 | 0.4% |
| Trade receivables | 75,212 | 76,884 | 1,672 | 2.2% |
| Financial assets | 0 | 0 | 0 | -98.1% |
| Other receivables | 19,239 | 24,026 | 4,787 | 24.9% |
| Income tax receivables | 2,769 | 1,031 | -1,738 | -62.8% |
| Cash and cash equivalents | 11,883 | 46,067 | 34,184 | 287.7% |
| Assets classified as held for sale | | | | |
| Other assets | | | | |
| SUM CURRENT ASSETS | 216,581 | 255,925 | 39,344 | 18.2% |
| SUM ASSETS | 424,677 | 463,425 | 38,748 | 9.1% |

| ALZCHEM GROUP (IN T€) | 31.12.2023 | 30.06.2024 | Deviation | |
|---|----------------|----------------|---------------|--------------|
| Share capital | 101,763 | 101,763 | | |
| RETAINED EARNINGS (+) / LOSS (-) | 144,979 | 159,346 | 14,367 | 9.9% |
| Other comprehensive income | -21,639 | -17,099 | 4,540 | -21.0% |
| Own shares | | | | |
| SHARE TO THE SHAREHOLDERS | 161,625 | 180,532 | 18,907 | 11.7% |
| Non-controlling interests | 1,934 | 2,020 | 85 | 4.4% |
| SUM EQUITY | 163,559 | 182,552 | 18,993 | 11.6% |
| Provisions for pensions | 100,294 | 94,692 | -5,601 | -5.6% |
| Other provisions | 19,691 | 22,146 | 2,455 | 12.5% |
| Loans | 48,665 | 44,249 | -4,416 | -9.1% |
| Finance lease liabilities | 3,377 | 2,857 | -519 | -15.4% |
| Trade liabilities | | | | |
| Other liabilities | 171 | | -171 | -100.0% |
| Deferred tax liabilities | 6,289 | 6,986 | 696 | 11.1% |
| SUM NON-CURRENT LIABILITIES | 178,487 | 170,930 | -7,557 | -4.2% |
| Other provisions | 3,537 | 3,704 | 167 | 4.7% |
| Loans | 8,833 | 9,303 | 470 | 5.3% |
| Finance lease liabilities | 1,613 | 1,661 | 48 | 3.0% |
| Finance liabilities | | | | |
| Trade liabilities | 31,554 | 51,471 | 19,917 | 63.1% |
| Other liabilities | 28,930 | 31,338 | 2,407 | 8.3% |
| Income tax liabilities | 8,164 | 12,467 | 4,303 | 52.7% |
| SUM CURRENT LIABILITIES | 82,631 | 109,943 | 27,312 | 33.1% |
| Sum EQUITY AND LIABILITIES | 424,677 | 463,425 | 38,748 | 9.1% |

PENSION ACCOUNTING (IFRS)

Alzchem Group (M€)



- Interest rates increased from 3.2% to 3.6% and led to a net pension decrease of 5.6 M€
- Pension trend (2.25%) and salary trend (3.00%) remain unchanged compared to December 31st, 2023
- Pension payments develop as expected with 1.1 M€ - pension obligation has a long maturity with approx. 30 years payout period

INCOME STATEMENT

Alzchem Group



| ALZCHEM GROUP (IN T€) | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Deviation (Q2) | |
|---|---------------|---------------|---------------|---------------|---------------|---------------|------------|------------|----------------|-------------|
| Revenue | 150,432 | 126,599 | 120,824 | 142,794 | 150,064 | 136,191 | | | 9,592 | 8% |
| Increase (+) / Decrease (-) in inventories of finished goods and work in progress | 916 | 9,105 | 147 | -13,972 | -6,521 | 12,682 | | | 3,577 | 39% |
| Other income | 5,574 | 1,906 | 3,104 | 3,274 | 3,558 | 3,731 | | | 1,826 | 96% |
| Raw materials and consumables used | -76,159 | -62,374 | -48,544 | -38,067 | -53,237 | -57,999 | | | 4,375 | -7% |
| Employee benefits expense | -35,262 | -36,012 | -34,678 | -39,684 | -40,589 | -42,468 | | | -6,456 | 18% |
| Other expense | -26,583 | -21,352 | -21,317 | -29,295 | -28,367 | -25,118 | | | -3,766 | 18% |
| EBITDA | 18,917 | 17,872 | 19,534 | 25,049 | 24,910 | 27,021 | | | 9,148 | 51% |
| Depreciation expense | -6,320 | -6,335 | -6,574 | -6,670 | -6,534 | -6,453 | | | -118 | 2% |
| Impairment | | | | | | | | | | |
| EBIT | 12,598 | 11,537 | 12,960 | 18,379 | 18,375 | 20,567 | | | 9,030 | 78% |
| Investment income | | | | | | | | | | |
| Other interest and similar income | 49 | 106 | 661 | -434 | 292 | 687 | | | 581 | 549% |
| Other interest and similar expense | -1,882 | -1,661 | -1,586 | -2,537 | -1,454 | -1,366 | | | 295 | -18% |
| Financial result | -1,832 | -1,555 | -925 | -2,971 | -1,162 | -679 | | | 876 | -56% |
| Result from associates | | | | | | | | | | |
| Result from ordinary business | 10,765 | 9,982 | 12,035 | 15,408 | 17,213 | 19,888 | | | 9,907 | 99% |
| Taxes on income and profit | -3,055 | -2,742 | -3,379 | -4,222 | -4,977 | -5,460 | | | -2,719 | 99% |
| <i>thereof income tax</i> | -2,946 | -2,716 | -3,015 | -6,431 | -4,463 | -5,036 | | | -2,321 | 85% |
| <i>thereof change from deferred taxes</i> | -109 | -26 | -364 | 2,209 | -514 | -424 | | | -398 | >1.000% |
| Annual result | 7,710 | 7,240 | 8,656 | 11,185 | 12,237 | 14,428 | | | 7,188 | 99% |
| <i>thereof minority interests</i> | 43 | 43 | 43 | 43 | 43 | 43 | | | | |
| <i>thereof shares held by shareholders</i> | 7,667 | 7,197 | 8,613 | 11,143 | 12,194 | 14,385 | | | 7,188 | 100% |
| Result per share in EUR | 0.76 € | 0.71 € | 0.85 € | 1.09 € | 1.20 € | 1.41 € | | | | |

INCOME STATEMENT

Alzchem Group



ALZCHEM GROUP (IN T€)

| | Q2 2023 | Q2 2024 | Deviation (QoQ) | | YTD Jun.2023 | YTD Jun.2024 | Deviation (YoY) | |
|---|---------------|---------------|-----------------|---------------|-----------------|-----------------|-----------------|---------------|
| Revenue | 126,599 | 136,191 | 9,592 | 7.6% | 277,031 | 286,255 | 9,224 | 3.3% |
| Increase (+) / Decrease (-) in inventories of finished goods and work in progress | 9,105 | 12,682 | 3,577 | 39.3% | 10,021 | 6,162 | -3,859 | -38.5% |
| Other income | 1,906 | 3,731 | 1,826 | 95.8% | 7,480 | 7,290 | -190 | -2.5% |
| Raw materials and consumables used | -62,374 | -57,999 | 4,375 | -7.0% | -138,533 | -111,236 | 27,297 | -19.7% |
| Employee benefits expense | -36,012 | -42,468 | -6,456 | 17.9% | -71,274 | -83,056 | -11,782 | 16.5% |
| Other expense | -21,352 | -25,118 | -3,766 | 17.6% | -47,935 | -53,484 | -5,549 | 11.6% |
| EBITDA | 17,872 | 27,021 | 9,148 | 51.2% | 36,789 | 51,930 | 15,141 | 41.2% |
| Depreciation expense | -6,335 | -6,453 | -118 | 1.9% | -12,655 | -12,988 | -333 | 2.6% |
| Impairment | 0 | 0 | 0 | | 0 | 0 | 0 | |
| EBIT | 11,537 | 20,567 | 9,030 | 78.3% | 24,134 | 38,942 | 14,808 | 61.4% |
| Investment income | 0 | 0 | 0 | | 0 | 0 | 0 | |
| Other interest and similar income | 106 | 687 | 581 | 549.3% | 155 | 979 | 824 | 531.4% |
| Other interest and similar expense | -1,661 | -1,366 | 295 | -17.8% | -3,542 | -2,820 | 722 | -20.4% |
| Financial result | -1,555 | -679 | 876 | -56.3% | -3,387 | -1,841 | 1,546 | -45.7% |
| Result from associates | 0 | 0 | 0 | | 0 | 0 | 0 | |
| Result from ordinary business | 9,982 | 19,888 | 9,907 | 99.2% | 20,747 | 37,102 | 16,354 | 78.8% |
| Taxes on income and profit | -2,742 | -5,460 | -2,719 | 99.2% | -5,797 | -10,437 | -4,640 | 80.0% |
| <i>thereof income tax</i> | -2,716 | -5,036 | -2,321 | 85.5% | -5,662 | -9,499 | -3,837 | 67.8% |
| <i>thereof change from deferred taxes</i> | -26 | -424 | -398 | >1.000% | -135 | -938 | -803 | 595.3% |
| Annual result | 7,240 | 14,428 | 7,188 | 99.3% | 14,950 | 26,664 | 11,714 | 78.4% |
| <i>thereof minority interests</i> | 43 | 43 | 0 | 0.0% | 85 | 85 | 0 | 0.0% |
| <i>thereof shares held by shareholders</i> | 7,197 | 14,385 | 7,188 | 99.9% | 14,865 | 26,579 | 11,714 | 78.8% |
| Result per share in EUR | 0.71 € | 1.41 € | 1 | 99.9% | 1.46 € | 2.61 € | 1 | 78.8% |

CASHFLOW STATEMENT

Alzchem Group



CASHFLOW (IN M€)

| | Q2 2023 | Q2 2024 | 1 - 6 2023 | 1 - 6 2024 |
|--|----------------|----------------|----------------|----------------|
| Consolidated earnings before taxes | 9,982 | 19,888 | 20,747 | 37,102 |
| Depreciation on fixed and intangible assets | 6,335 | 6,453 | 12,655 | 12,988 |
| Decrease in pension provisions | -403 | -471 | -967 | -1,104 |
| Loss (+) / Profit (-) from the sale of non-current assets | 0 | -2 | -1 | -3 |
| Other non-cash income (-) and expenses (+) | 1,454 | 4,777 | 2,914 | 7,887 |
| Financial result | 1,555 | 679 | 3,387 | 1,841 |
| Interests & Taxes | -2,776 | -2,910 | -5,446 | -3,863 |
| Increase (+) / Decrease (-) Net Working Capital | 13,423 | 1,963 | 6,524 | 8,982 |
| Cashflow from ongoing operations (Net cash flow) | 29,570 | 30,379 | 39,814 | 63,829 |
| Cash outflows for investments in fixed assets | -3,768 | -5,543 | -8,577 | -12,439 |
| Cash inflows from the sale of fixed assets | 29 | 2 | 1 | 3 |
| Cash inflows from the disposal of investments | | | | |
| Cashflow from investing activity | -3,739 | -5,541 | -8,577 | -12,436 |
| Free cashflow | 25,831 | 24,838 | 31,238 | 51,394 |
| Deposits (+) / Repayment (-) bank loans long-term | | | 30,000 | |
| Repayment of bank loans long-term | -2,514 | -2,208 | -5,027 | -3,979 |
| Deposits (+) / Repayment (-) from short-term financing lines | -10,791 | | -44,033 | |
| Dividend payments | -10,685 | -12,212 | -10,685 | -12,212 |
| Payment of reduction in leasing liabilities | -440 | -425 | -896 | -898 |
| Payments for the acquisition of own shares (incl. transaction costs) | | | | |
| Payments to non-controlling interests | | | -171 | -171 |
| Cashflow from financing activity | -24,430 | -14,845 | -30,812 | -17,260 |
| Net increase / decrease in cash and cash equivalents | 1,401 | 9,993 | 426 | 34,134 |

SEGMENT OVERVIEW BY QUARTER

Alzchem Group



SALES


| SALES | 2022 | | | | 2023 | | | | 2024 | | | | Deviation PY (Q2) | |
|----------------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------|----------|-------------------|-----------|
| | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | T€ | % |
| Basics & Intermediates | 57,441 | 57,927 | 59,557 | 52,614 | 57,337 | 46,038 | 44,271 | 44,538 | 49,299 | 41,848 | | | -4,190 | -9% |
| Specialty Chemicals | 65,279 | 76,214 | 72,967 | 73,902 | 85,783 | 73,172 | 69,545 | 91,302 | 92,961 | 85,805 | | | 12,633 | 17% |
| Other and Holding | 6,675 | 6,294 | 6,670 | 6,684 | 7,312 | 7,389 | 7,007 | 6,955 | 7,804 | 8,538 | | | 1,149 | 16% |
| <i>Group Consolidation</i> | | | | | | | | | | | | | | |
| Alzchem Group | 129,395 | 140,435 | 139,193 | 133,200 | 150,432 | 126,599 | 120,824 | 142,794 | 150,064 | 136,191 | | | 9,592 | 8% |

EBITDA

| EBITDA | 2022 | | | | 2023 | | | | 2024 | | | | Deviation PY (Q2) | |
|----------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|----------|----------|-------------------|------------|
| | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | Q1 T€ | Q2 T€ | Q3 T€ | Q4 T€ | T€ | % |
| Basics & Intermediates | 2,841 | 853 | -2,621 | 3,910 | 2,780 | 2,410 | 1,065 | 3,275 | 1,802 | 3,055 | | | 645 | 27% |
| Specialty Chemicals | 14,267 | 16,322 | 14,637 | 7,789 | 16,019 | 14,936 | 18,541 | 23,747 | 22,684 | 22,843 | | | 7,907 | 53% |
| Other and Holding | -139 | 830 | 1,038 | 230 | 475 | 438 | 721 | -1,171 | 537 | 849 | | | 410 | 94% |
| <i>Group Consolidation</i> | 103 | -200 | -905 | 2,487 | -357 | 88 | -793 | -802 | -113 | 274 | | | 186 | 212% |
| Alzchem Group | 17,072 | 17,805 | 12,149 | 14,416 | 18,917 | 17,872 | 19,534 | 25,049 | 24,910 | 27,021 | | | 9,149 | 51% |

ALZCHEM GROUP LOCATIONS

Production sites and sales companies



IMPLEMENTING OPERATING TARGETS 2024

Focus on the key growth drivers and sustainability



IMPROVEMENT

- Pass on raw material price increases to the market
- Flexibilization of production and processes
- Volume growth & full capacity utilization




GROWTH

- Increase the availability of Creamino® worldwide
- Examine growth opportunities in USA
- Accompany market growth of Creapure® through additional CAPEX
- Embed Eminex® on the certificate market



SUSTAINABILITY

- Vision 0 accidents and 0 waste
- Realization of climate roadmap
- Implement EU Taxonomy Regulation and CSRD in an audit-ready manner
- Enjoyment of work – realization of the feedback from the employee survey




“VERBUND” – FULLY INTEGRATED BUSINESS MODEL

Benefits of the “Verbund” system approach



○ Segment
Specialty Chemicals

○ Segment
Basics & Inter-
mediates



BENEFITS OF “VERBUND”

- Full control of product quality and specifications
- Lower costs
- Higher financial predictability
- Certainty of supply
- Well positioned to address niche markets
- Economies of scale
- Low carbon footprint

MEGATRENDS AS GROWTH DRIVERS



POPULATION
GROWTH



LONGER LIFE
EXPECTANCY



CLIMATE
CHANGE



SUSTAINA-
BILITY



SAFETY &
DEFENCE

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries






| | MAIN PRODUCTS | DESCRIPTION | END-MARKETS |
|------------------------|--|---|--|
| SPECIALTY CHEMICALS | CREAMINO [®] | A nutritional additive for poultry and pigs | Feed additive |
| | Creapure [®] | Creapure [®] , premium brand for creatine monohydrate as ingredient in sports & health nutrition | Food supplements |
| | LIVA DUR | Dietary supplement with pure creatine | Food supplements |
| | Creavitalis [®] | Creatine for health and food applications | Food supplements |
| | Dormex [®] | Plant growth regulator used in fruit production | Agriculture |
| | BREATHRU'S 301 | Additive for plant protection formulations | Agriculture |
| | Sitofex [®] | Plant growth regulator used in fruit production | Agriculture |
| | Silzot HQ | Silicon nitride powder for ceramic applications | Ceramics |
| | Bioselect [®] | Highly purified form of guanidine salts | Pharmaceuticals / API |
| | Cyanamide | An organic compound widely used in agriculture and pharmaceuticals | Agriculture and pharmaceuticals |
| | DYHARD [®] | Hardeners and accelerators in powder, paste and liquid form | Hardener & Accelerator Systems for Composite Materials |
| | Thiourea | Various applications incl. flotation agents and pharmaceutical raw materials | Mining and pharmaceuticals |
| Nitroguanidine | Intermediates for explosives and agrochemical products | Agriculture, Automotive, Defense | |

OUR PRODUCTS AND MARKETS

Successful with proven and new products in various industries



| | MAIN PRODUCTS | DESCRIPTION | END-MARKETS |
|------------------------|---|---|-------------------------------|
| BASICS & INTERMEDIATES |  CaD [®] | Calcium carbide-based mixtures for hot metal desulphurization | Steel industry |
| | Guanidine Salts | Fuel for airbags, key production of the intermediate product | Automotive |
| | Dicyandiamide | Versatile intermediate in various markets including the pharmaceutical industry | Pharmaceutical Agriculture |
| | NITRALZ[®] | Business fields in color, agro and pharmaceutical applications | Pigments Pharmaceutical |
| |  Eminex [®] | Reduction of methane emissions during storage of manure | Agriculture |
| |  Perlka [®] | Special calcium cyanamide multi-effect fertilizer | Agriculture |
| OTHER & HOLDING | <p>Operation of the Trostberg Chemical Park (companies located at the site: Alzchem, BASF, Master Builders Solution, Sika, Firmenich, Aramark, VIACTIV)</p> <p>Site services</p> <p>Other activities not included in the "Specialty Chemicals" or "Basics & Intermediates" segments</p> | | |

KEY SHARE DATA

Share details as of July 30, 2024



SHARES OUTSTANDING 10,176,335

LAST CLOSING PRICE EUR 49.80

MARKET CAPITALIZATION EUR 507 m

TICKER ACT


WKN A2YNT3

ISIN DE000A2YNT30

LISTING Frankfurt Stock Exchange – Prime Standard

DESIGNATED SPONSOR Baader Bank AG
ODDO BHF SE

SHAREHOLDER STRUCTURE



As of June 2024. The information on the shareholders is based on the figures reported to us by them. Data regarding the free float are provided in accordance with section 2.3 of the "Guide to the DAX Equity Indices."